These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Systems level metabolic phenotype of methotrexate administration in the context of non-alcoholic steatohepatitis in the rat. Kyriakides M; Hardwick RN; Jin Z; Goedken MJ; Holmes E; Cherrington NJ; Coen M Toxicol Sci; 2014 Nov; 142(1):105-16. PubMed ID: 25145655 [TBL] [Abstract][Full Text] [Related]
3. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Vlaming ML; van Esch A; Pala Z; Wagenaar E; van de Wetering K; van Tellingen O; Schinkel AH Mol Cancer Ther; 2009 Dec; 8(12):3350-9. PubMed ID: 19996279 [TBL] [Abstract][Full Text] [Related]
4. Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Vlaming ML; Pala Z; van Esch A; Wagenaar E; de Waart DR; van de Wetering K; van der Kruijssen CM; Oude Elferink RP; van Tellingen O; Schinkel AH Clin Cancer Res; 2009 May; 15(9):3084-93. PubMed ID: 19383815 [TBL] [Abstract][Full Text] [Related]
5. Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Wang Z; Zhou Q; Kruh GD; Gallo JM Drug Metab Dispos; 2011 Nov; 39(11):2155-61. PubMed ID: 21841039 [TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. Hardwick RN; Fisher CD; Street SM; Canet MJ; Cherrington NJ Drug Metab Dispos; 2012 Mar; 40(3):450-60. PubMed ID: 22112382 [TBL] [Abstract][Full Text] [Related]
7. A Pharmacokinetic Natural Product-Disease-Drug Interaction: A Double Hit of Silymarin and Nonalcoholic Steatohepatitis on Hepatic Transporters in a Rat Model. Montonye ML; Tian DD; Arman T; Lynch KD; Hagenbuch B; Paine MF; Clarke JD J Pharmacol Exp Ther; 2019 Nov; 371(2):385-393. PubMed ID: 31420525 [TBL] [Abstract][Full Text] [Related]
8. Gene-by-Environment Interaction of Bcrp Toth EL; Li H; Dzierlenga AL; Clarke JD; Vildhede A; Goedken M; Cherrington NJ Drug Metab Dispos; 2018 Nov; 46(11):1478-1486. PubMed ID: 30166404 [TBL] [Abstract][Full Text] [Related]
9. Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Hardwick RN; Fisher CD; Canet MJ; Scheffer GL; Cherrington NJ Drug Metab Dispos; 2011 Dec; 39(12):2395-402. PubMed ID: 21878559 [TBL] [Abstract][Full Text] [Related]
13. Asking the Right Questions With Animal Models: Methionine- and Choline-Deficient Model in Predicting Adverse Drug Reactions in Human NASH. Li H; Toth E; Cherrington NJ Toxicol Sci; 2018 Jan; 161(1):23-33. PubMed ID: 29145614 [TBL] [Abstract][Full Text] [Related]
14. Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate. Vlaming ML; van Esch A; van de Steeg E; Pala Z; Wagenaar E; van Tellingen O; Schinkel AH Drug Metab Dispos; 2011 Aug; 39(8):1338-44. PubMed ID: 21566011 [TBL] [Abstract][Full Text] [Related]
15. Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir. Laho T; Clarke JD; Dzierlenga AL; Li H; Klein DM; Goedken M; Micuda S; Cherrington NJ Biochem Pharmacol; 2016 Sep; 115():144-51. PubMed ID: 27381944 [TBL] [Abstract][Full Text] [Related]
16. Effects of Nonalcoholic Fatty Liver Disease on Hepatic CYP2B1 and in Vivo Bupropion Disposition in Rats Fed a High-Fat or Methionine/Choline-Deficient Diet. Cho SJ; Kim SB; Cho HJ; Chong S; Chung SJ; Kang IM; Lee JI; Yoon IS; Kim DD J Agric Food Chem; 2016 Jul; 64(27):5598-606. PubMed ID: 27321734 [TBL] [Abstract][Full Text] [Related]
17. Effect of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a human tumor necrosis factor alpha-converting enzyme inhibitor, on the disposition of methotrexate: a transporter-based drug-drug interaction case study. Luo G; Garner CE; Xiong H; Hu H; Richards LE; Brouwer KL; Duan J; Decicco CP; Maduskuie T; Shen H; Lee FW; Gan LS Drug Metab Dispos; 2007 Jun; 35(6):835-40. PubMed ID: 17332143 [TBL] [Abstract][Full Text] [Related]